CompoAtlas

Women's Ultra Mega Menopause Vitapak

Testo originale in francese.

Women's Ultra Mega Menopause Vitapak, NPN 80051771: prodotto di salute naturale autorizzato in Canada. Ingredienti medicinali: Zingiber officinale, Vitex agnus-castus, Vitamine B6, Salvia miltiorrhiza.

Se questo prodotto fosse venduto in Francia

Si calcola una quantità giornaliera solo per una posologia orale esplicita per adulti, espressa al giorno e in un’unità solida corrispondente alla forma del prodotto. Unità ambigue, liquidi, polveri e dosi pediatriche non vengono estrapolati. Una quantità non calcolata non viene confrontata con i limiti di dose. Questa analisi non costituisce un’autorizzazione alla vendita in Francia né una valutazione di sicurezza o efficacia.

Composizione

Ingrediente medicinale e fontePer unità posologica, secondo la fonteMassimo giornaliero, adulto
Zingiber officinale

Fonte : Rhizome

10 mgNon calcolata
Vitex agnus-castus

Fonte : Fruit

30 mgNon calcolata
Vitamine B6

Fonte : Chlorhydrate de pyridoxine

25 mgNon calcolata
Salvia miltiorrhiza

Fonte : Racine

Rapporto di estrazione : 4:1

Equivalente di pianta secca : 30 mg

7,5 mgNon calcolata
Vitex agnus-castus

Fonte : Fruit

5 mgNon calcolata
Sambucus nigra

Fonte : Fruit

Rapporto di estrazione : 4:1

Equivalente di pianta secca : 20 mg

5 mgNon calcolata
Camellia sinensis

Fonte : Feuille

Potenza : 50 % Polyphenols

7,5 mgNon calcolata
Manganèse

Fonte : Sulfate de manganèse

4,5 mgNon calcolata
Iode

Fonte : Iodure de potassium

85 mcgNon calcolata
Hordeum vulgare

Fonte : Feuille

Rapporto di estrazione : 4:1

Equivalente di pianta secca : 10 mg

2,5 mgNon calcolata
Inositol

Fonte : Inositol

12,5 mgNon calcolata
Bioflavonoïdes d'agrumes

Fonte : Citrus paradisi - Pelure (fruit)

7,5 mgNon calcolata
Bioflavonoïdes d'agrumes

Fonte : Citrus limon - Pelure (fruit)

7,5 mgNon calcolata
Bioflavonoïdes d'agrumes

Fonte : Citrus sinensis - Pelure de fruit

7,5 mgNon calcolata
Acide 4-aminobenzoïque

Fonte : 4-aminobenzoic acid

5 mgNon calcolata
Rosa canina

Fonte : Fruit

100 mcgNon calcolata
1-Carboxy-N,N,N-chlorure de triméthylméthanaminium7,5 mgNon calcolata
Capsicum annuum

Fonte : Fruit

1 mgNon calcolata
Malpighia glabra

Fonte : Fruit

Potenza : 25 % Vitamin C

200 mcgNon calcolata
Thiamine

Fonte : Chlorhydrate de thiamine

15 mgNon calcolata
Magnésium

Fonte : Oxyde de magnésium

150 mgNon calcolata
Magnésium

Fonte : Magnesium hydrolyzed vegetable protein (HVP) chelate

150 mgNon calcolata
Niacinamide

Fonte : Niacinamide

7,5 mgNon calcolata
Calcium

Fonte : Carbonate de calcium

300 mgNon calcolata
Calcium

Fonte : Produit de chléation de calcium et de PVH

300 mgNon calcolata
Silicium

Fonte : Dioxyde de silicium

1 mgNon calcolata
bêta-carotène

Fonte : bêta-carotène

Potenza : 1.875 UI

1.125 mcgNon calcolata
Vitamine A

Fonte : Palmitate de vitamine A

Potenza : 1.250 UI

375 mcg EARNon calcolata
Vitamine D

Fonte : Cholécalciférol

Potenza : 200 UI

5 mcgNon calcolata
Vitamine E

Fonte : Acétate de d-alpha tocophéryle

Potenza : 50 UI

33,5 mg ATNon calcolata
Vitamin K1

Fonte : Vitamine K1

7,5 mcgNon calcolata
Vitamine C

Fonte : Ascorbate de calcium

150 mgNon calcolata
Riboflavine

Fonte : Riboflavine

15 mgNon calcolata
Niacine

Fonte : Acide nicotinique

10 mgNon calcolata
Vitamine B12

Fonte : Cyanocobalamine

75 mcgNon calcolata
Folate

Fonte : Acide folique

500 mcgNon calcolata
Biotine

Fonte : Biotine

125 mcgNon calcolata
Acide pantothénique

Fonte : D-Pantothénate de calcium

25 mgNon calcolata
Zinc

Fonte : Produit de chélation de zinc et de protéine végétale hydrolysée (PVH)

5 mgNon calcolata
Ginkgo biloba

Fonte : Feuille

5 mgNon calcolata
Vaccinium myrtillus

Fonte : Fruit

Rapporto di estrazione : 100:1

Equivalente di pianta secca : 600 mg

6 mgNon calcolata
Oenothera biennis

Fonte : Graine(s)

Potenza : 910 mg Linoleic Acid

1.300 mgNon calcolata
Oenothera biennis

Fonte : Graine(s)

Potenza : 100 mg Gamma Linolenic Acid

Non precisataNon calcolata
Actaea racemosa

Fonte : Racine

160 mgNon calcolata
Cuivre

Fonte : Copper HVP chelate

1 mgNon calcolata
Potassium

Fonte : Chlorure de potassium

15 mgNon calcolata
Chrome

Fonte : Picolinate de chrome

50 mcgNon calcolata
Sélénium

Fonte : Produit de chélation de sélénium et de protéine végétale hydrolysée (PVH)

50 mcgNon calcolata
Boron

Fonte : Citrate de bore

350 mcgNon calcolata
Molybdène

Fonte : Citrate de molybdène

20 mcgNon calcolata
Vanadium

Fonte : Citrate de vanadium

15 mcgNon calcolata
Choline

Fonte : Bitartrate de choline

12,5 mgNon calcolata

Ingredienti non medicinali

Gélatine, Poly(éthylène glycol), Cellulose microcristalline, Laque d'aluminiium FD&C rouge n° 40, Ethylcellulose, Dioxyde de silicium, Glycérine, Stéarate de magnésium, Acide stéarique, Acide oléique, Talc, Hydroxyde d'ammonium, FD&C Blue No.2 Aluminum Lake, Poly(alcool vinylique), Dioxyde de titane, triglycérides à chaînes moyennes, Sodium alginate

Dosi raccomandate in Canada

PopolazioneEtàQuantità per assunzioneFrequenza
Adultes de sexe fémininNon précisée1 Vitapak1 Tous les jours

Usi autorizzati in Canada

A factor in the maintenance of good health. Helps in the development and maintenance of bones, cartilage, teeth and gums. Helps to maintain eyesight, membranes, immune function, healthy skin and proper muscle function. Provides support for healthy glucose metabolism. Helps to produce and repair connective tissue. Calcium intake, when combined with sufficient vitamin D, a healthy diet, and regular exercise, may reduce the risk of developing osteoporosis. An antioxidant for the maintenance of good health. Source of essential fatty acids, omega-3 fatty acids, and omega-6 fatty acids for the maintenance of good health. Helps support cognitive health and/or brain function. Helps maintain and support cardiovascular health.Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flushes; to help support healthy mood balance during menopause; to help ease nervous tension (calmative); to help relieve pain associated with menstruation; to help relieve premenstrual symptoms.

Testo originale in inglese.

Un uso autorizzato in Canada non è un’indicazione sulla salute autorizzata nell’Unione europea. Consulti il registro delle indicazioni sulla salute.

Avvertenze in Canada

Cautions and Warnings : Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are taking sulfonamides and/or if you have an iron deficiency; if you have stomach ulcers or inflammation; if you are taking blood thinners; if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy; if you have high blood pressure; if you are taking antidepressants. If you have a liver disorder, consult a health care practitioner prior to use. Stop use if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite and consult a health care practitioner.

Testo originale in inglese.

Contra-Indications : Do not use if you are pregnant or breastfeeding.

Testo originale in inglese.

Known Adverse Reactions : Hypersensitivity (e.g. allergy) has been known to occur; in which case, discontinue use. People sensitive to nicotinic acid may experience flushing of the skin that is generally mild and transient. Rare, unpredictable cases of liver injury associated with green tea extract-containing products have been reported (in Canada and internationally).

Testo originale in inglese.

Scheda del prodotto

Titolare
GNC Canada Holdings ULC
NPN o DIN-HM
80051771
Stato
Licenza non attiva
Data della licenza
13 giugno 2014
Data di revisione
Non indicata
Forma
Kit
Via di somministrazione
Orale
Tipo di domanda
Non traditionnelle

Fonte

Scheda ufficiale Health Canada, licenza 80051771

Banca dati dei prodotti naturali per la salute autorizzati (BDPSNH), Health Canada: prodotti autorizzati, ingredienti, dosi, usi e avvertenze, consultato il 27 ottobre 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Testo originale in inglese.

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

Testo originale in francese.

La formula venduta in Europa con lo stesso nome può essere diversa. Queste informazioni non sostituiscono il parere di un medico o farmacista.

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Zingiber officinale
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    GINGER - ZINGIBER OFFICINALE

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 19 dicembre 2025

  • Vitex agnus-castus
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    CHASTE TREE - VITEX AGNUS-CASTUS

    Via di somministrazione: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).

    Fonti citate da Health Canada (4)
    • Bradley PR, editor. 2006. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Controindicazioni

    Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).

    Fonti citate da Health Canada (9)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. 2000. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Dugoua JJ, Seely D, Pern D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex Agnus-Castus) during pregnancy and lactation. Can J. Clin Pharmacol 2008;15(1);e74-e79.
    • EMA 2018. European Medicines Agency. European Union herbal monograph on Vitex agnus-castus L., fructus. London (GB): EMA Committee on Herbal Medicinal Products (HMPC); 27 March 2018. [Accessed 2024 February 29] Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-vitex-agnus-castus-l-fructus-revision-1_en.pdf
    • ESCOP 2003: European Scientific Cooperative on Phytotherapy Scientific Committee. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy in collaboration with Thieme.
    • Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Toronto (ON): Churchill Livingstone.
    • Najib FS, Poordast T, Mahmudi MS, Shiravani Z, Namazi N, Omrani GR. Does Vitex Agnus-Castus L. Have Deleterious Effect on Fertility and Pregnancy Outcome? An Experimental Study on Rats for Prediction of Its Safety. J. Pharmacopuncture 2022;25(2):106-113. PubMed
    • WHO 2009: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4. Geneva (CH): World Health Organization.
    • OMS 2009: Organisation mondiale de la santé. WHO Monographs on Selected Medicinal Plants, Volume 4. Genève (CH): Organisation mondiale de la santé.

    Monografia di Health Canada del 28 marzo 2024

  • Sambucus nigra
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    ELDER – SAMBUCUS

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condizione di applicazione: Diaphoretic; Symptoms of colds, flus; Sinusitis, hay-fever; Joint pain.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Reazioni avverse note

    Condizione di applicazione: All products.

    Stop use if hypersensitivity/allergy occur (Forster-Waldl et al. 2003).

    Fonti citate da Health Canada (1)
    • Förster-Waldl E, Marchetii M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Jäger S, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Type I allergy to elderberry (Sambucus nigra) is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins. Clinical and Experimental Allergy 2003;33(2):1703-1710. PubMed

    Condizione di applicazione: All products except those making a diuretic claim.

    When using this product diuretic effect may occur (Bradley 1992; Winston and Kuhn 2008; Barnes et al. 2007; Hoffman 2003).

    Fonti citate da Health Canada (2)
    • Barnes J, Anderson LA, Philipson JD. Herbal Medicines. 3rd edition. London (GB): The Pharmaceutical Press; 2007.
    • Winston D and Kuhn MA. Herbal Therapy & Supplements A Scientific and Traditional Approach. Philadelphia (PA): Lippincott Williams & Wilkins; 2008.

    2 studi citati nel testo non hanno un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Monografia di Health Canada del 19 dicembre 2025

  • Capsicum annuum
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    CAYENNE - CAPSICUM ANNUUM Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    Fonti citate da Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    Fonti citate da Health Canada (2)
    • Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    Fonti citate da Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Condizione di applicazione: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 27 marzo 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    For external use only (US FDA 2023).

    Fonti citate da Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    Fonti citate da Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    Fonti citate da Health Canada (1)
    • US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf

    1 studio citato nel testo non ha un riferimento corrispondente nella monografia (vedi le anomalie nella pagina delle fonti).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    Fonti citate da Health Canada (1)
    • CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Reazioni avverse note

    Condizione di applicazione: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    Fonti citate da Health Canada (5)
    • APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
    • Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
    • McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Studio randomizzato
    • Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Revisione sistematica

    Monografia di Health Canada del 27 marzo 2026

  • Vitamine D
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    VITAMIN D (>1,000 - 2,500 IU)

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products except products containing zinc sourced from picolinate requiring a contraindication.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney disorders (NIH 2024; BfR 2020).

    Fonti citate da Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking other supplements or products containing vitamin D or vitamin D analogues.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking any medications including antacids, anticonvulsants, digoxin, cholestyramine, colestipol, mineral oil, steroids, statins or thiazide diuretics (NNHPD 2021; BfR 2020).

    Fonti citate da Health Canada (3)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NNHPD 2021. Natural and Non-Prescription Health Products Directorate. Internal evidence and HC's product monographs.
    • DPSNSO 2021. Direction des produits de santé naturels et sans ordonnance. Preuves internes et monographies de produits internes de SC.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to determine if you would benefit from additional vitamin D as 15-20 mcg (600-800 IU) of vitamin D per day is an adequate quantity for most individuals.

    Si applica ai prodotti: containing vitamin K2.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Si applica ai prodotti: providing 25-34 mg of zinc per day for adults 18 years or 31-50 mg of zinc per day for adults 19 years and older.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are unsure whether you are taking enough copper as zinc supplementation can cause a copper deficiency (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Controindicazioni

    Condizione di applicazione: All products.

    Do not use if you have hypercalcemia and/or hypercalciuria (NIH 2024; BfR 2020).

    Fonti citate da Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Si applica ai prodotti: containing zinc sourced from picolinate.

    Do not use if you are pregnant or breastfeeding (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Reazioni avverse note

    Condizione di applicazione: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if the following early symptoms of hypercalcemia occur: weakness, fatigue, drowsiness, headache, lack of appetite, dry mouth, metallic taste, nausea, vomiting, vertigo, ringing in the ears, lack of coordination and muscle weakness or if you develop any other symptom (NIH 2024; BfR 2020).

    Fonti citate da Health Canada (2)
    • BfR 2020: Vitamin D: consumption of high-dose food supplements is unnecessary; BfR Opinion No 035; 2020. [Accessed 2026March 18]. Available from: https://www.bfr.bund.de/cm/349/vitamin-d-consumption-of-high-dose-food-supplements-is-unnecessary.pdf
    • NIH 2024: National Institute of Health: Vitamin D Fact Sheet for Health Professionals; 2024. [Accessed 2026 March 18]. Available from: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

    Si applica ai prodotti: providing more than 350 mg of magnesium per day.

    When using this product you may experience diarrhea (NNHPD 2026).

    Fonti citate da Health Canada (2)
    • NNHPD 2026: Natural and Non-Prescription Health Products Directorate. Multi-Vitamin/Mineral Supplements monograph. [Accessed 2026 May 29]. Available from: https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=eng
    • DPSNSO 2026. Direction des produits de santé naturels et sans ordonnance. Monographies des suppléments de multivitamines et minéraux [Consulté le 29 mai 2026]. Disponible à : https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=multi_vitmin_suppl3&lang=fre

    Monografia di Health Canada del 26 giugno 2026

  • Ginkgo biloba
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    GINKGO - GINKGO BILOBA

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Fonti citate da Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
    • OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    Fonti citate da Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Controindicazioni

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    Fonti citate da Health Canada (1)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    Fonti citate da Health Canada (3)
    • Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Revisione sistematica
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Monografia di Health Canada del 25 luglio 2025

  • Vaccinium myrtillus
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Via di somministrazione: Buccal (Blumenthal et al. 2000)

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 30 gennaio 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Via di somministrazione: Oral (Blumenthal et al. 2000)

    Precauzioni e avvertenze

    Condizione di applicazione: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Monografia di Health Canada del 25 ottobre 2024

  • Oenothera biennis
    Leggere l'avvertenza, quando si applica e gli studi citati
  • Actaea racemosa
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    Black Cohosh - Actaea Racemosa

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).

    Fonti citate da Health Canada (6)
    • Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause: the Journal of the North American Menopause Society 2004;11(5):575-577. PubMed Caso clinico
    • EMA 2018: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC). European Union Herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizome. March 2018. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cimicifuga-racemosa-l-nutt-rhizome-revision-1_en.pdf
    • EMA 2007: European Medicines Agency. Committee on Herbal Medicinal Products (HMPC) Annex 1. Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (Black cohosh, root). London (UK): European Medicines Agency; May 20027. [Accessed 2025 January 3]. Available from: https://www.ema.europa.eu/en/documents/herbal-report/assessment-case-reports-connected-herbal-medicinal-products-containing-cimicifugae-racemosae-rhizoma-black-cohosh-root_en.pdf
    • Lynch CR, Folkers ME, Hutson WR. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transplantation 2006;12(6):989-992. PubMed Caso clinico
    • Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. New York (NY): Taylor and Francis; 2006.
    • NIH 2004: National Institutes of Health. Workshop on the Safety of Black Cohosh in Clinical Studies. Bethesda (MD): National Institutes of Health, Department of Health and Human Services; November 22, 2004. [Accessed 2024 December 3]. Available from: https://files.nccih.nih.gov/s3fs-public/news/blackcohosh_mtngsumm.pdf

    Controindicazioni

    Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).

    Fonti citate da Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
    • Tilgner S. Herbal Medicine from the Heart of the Earth Creswell (OR): Wise Acre Press; 1999.

    Monografia di Health Canada del 31 gennaio 2025

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

La data della prova di questo elenco di ingredienti è sconosciuta.

Il prodotto è cambiato? Fotografi la confezione.

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Invio per analizzare, Maiusc+Invio per una nuova riga